TY - JOUR
T1 - An integrated multi-omic approach demonstrates distinct molecular signatures between human obesity with and without metabolic complications
T2 - a case–control study
AU - Mir, Fayaz Ahmad
AU - Mall, Raghvendra
AU - Ullah, Ehsan
AU - Iskandarani, Ahmad
AU - Cyprian, Farhan
AU - Samra, Tareq A.
AU - Alkasem, Meis
AU - Abdalhakam, Ibrahem
AU - Farooq, Faisal
AU - Taheri, Shahrad
AU - Abou-Samra, Abdul Badi
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/3/29
Y1 - 2023/3/29
N2 - Objectives: To examine the hypothesis that obesity complicated by the metabolic syndrome, compared to uncomplicated obesity, has distinct molecular signatures and metabolic pathways. Methods: We analyzed a cohort of 39 participants with obesity that included 21 with metabolic syndrome, age-matched to 18 without metabolic complications. We measured in whole blood samples 754 human microRNAs (miRNAs), 704 metabolites using unbiased mass spectrometry metabolomics, and 25,682 transcripts, which include both protein coding genes (PCGs) as well as non-coding transcripts. We then identified differentially expressed miRNAs, PCGs, and metabolites and integrated them using databases such as mirDIP (mapping between miRNA-PCG network), Human Metabolome Database (mapping between metabolite-PCG network) and tools like MetaboAnalyst (mapping between metabolite-metabolic pathway network) to determine dysregulated metabolic pathways in obesity with metabolic complications. Results: We identified 8 significantly enriched metabolic pathways comprising 8 metabolites, 25 protein coding genes and 9 microRNAs which are each differentially expressed between the subjects with obesity and those with obesity and metabolic syndrome. By performing unsupervised hierarchical clustering on the enrichment matrix of the 8 metabolic pathways, we could approximately segregate the uncomplicated obesity strata from that of obesity with metabolic syndrome. Conclusions: The data suggest that at least 8 metabolic pathways, along with their various dysregulated elements, identified via our integrative bioinformatics pipeline, can potentially differentiate those with obesity from those with obesity and metabolic complications.
AB - Objectives: To examine the hypothesis that obesity complicated by the metabolic syndrome, compared to uncomplicated obesity, has distinct molecular signatures and metabolic pathways. Methods: We analyzed a cohort of 39 participants with obesity that included 21 with metabolic syndrome, age-matched to 18 without metabolic complications. We measured in whole blood samples 754 human microRNAs (miRNAs), 704 metabolites using unbiased mass spectrometry metabolomics, and 25,682 transcripts, which include both protein coding genes (PCGs) as well as non-coding transcripts. We then identified differentially expressed miRNAs, PCGs, and metabolites and integrated them using databases such as mirDIP (mapping between miRNA-PCG network), Human Metabolome Database (mapping between metabolite-PCG network) and tools like MetaboAnalyst (mapping between metabolite-metabolic pathway network) to determine dysregulated metabolic pathways in obesity with metabolic complications. Results: We identified 8 significantly enriched metabolic pathways comprising 8 metabolites, 25 protein coding genes and 9 microRNAs which are each differentially expressed between the subjects with obesity and those with obesity and metabolic syndrome. By performing unsupervised hierarchical clustering on the enrichment matrix of the 8 metabolic pathways, we could approximately segregate the uncomplicated obesity strata from that of obesity with metabolic syndrome. Conclusions: The data suggest that at least 8 metabolic pathways, along with their various dysregulated elements, identified via our integrative bioinformatics pipeline, can potentially differentiate those with obesity from those with obesity and metabolic complications.
KW - Abdominal obesity
KW - Acid
KW - Atherosclerosis
KW - Cardiovascular-disease
KW - Diabetes-mellitus
KW - Healthy obesity
KW - Individuals
KW - Myocardial-infarction
KW - Prevalence
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=85151207525&partnerID=8YFLogxK
U2 - 10.1186/s12967-023-04074-x
DO - 10.1186/s12967-023-04074-x
M3 - Article
C2 - 36991398
AN - SCOPUS:85151207525
SN - 1479-5876
VL - 21
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 229
ER -